Phenylketonuria (PKU) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Phenylketonuria
(PKU) Market Outlook
Thelansis’s “Phenylketonuria
(PKU) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2025 To 2035” covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Phenylketonuria
(PKU) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Phenylketonuria
(PKU) Overview
Phenylketonuria (PKU) is a rare,
autosomal recessive metabolic disorder caused by mutations in the PAH gene,
which codes for the hepatic enzyme phenylalanine hydroxylase. This deficiency
prevents the crucial conversion of the essential amino acid phenylalanine (Phe)
into tyrosine, driving toxic Phe accumulation in the blood and brain. If left
unmanaged, neurotoxicity triggers irreversible intellectual disabilities,
microcephaly, and severe psychiatric symptoms. Historically controlled
through a highly restrictive, low-protein diet and specialized medical
foods, modern pharmacology has transformed PKU management. For
patients with residual enzyme activity, the standard synthetic cofactor
sapropterin (Kuvan) has been supplemented by the FDA approval of
Sephience (sepiapterin). As a natural precursor to the BH4 cofactor with
independent chaperone effects, oral sepiapterin drastically outperforms legacy
options, liberalizing dietary protein tolerance. For severe, non-responsive
adult and adolescent phenotypes, BioMarin’s Palynziq (pegvaliase-pqpz)—an
injectable PEGylated enzyme substitution therapy—metabolizes Phe independently
of the defective PAH pathway, with its label expanded to adolescents aged 12
and older. The pipeline is actively shifting toward universal, genotype-independent
mechanisms like Otsuka’s repinatrabit (JNT-517), an oral small molecule
blocking renal Phe reabsorption in Phase 3 trials, alongside Beam Therapeutics’
BEAM-304, an in vivo base-editing candidate cleared for Phase 1/2 trials to
permanently correct PAH mutations. Early diagnosis via
universal newborn screening and the rapid deployment of these molecular
therapies now ensure excellent neurocognitive outcomes.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment